Literatur

S. Arnold; G. Kluger

doi:10.1055/s-0038-1628757

Nervenheilkunde, Inhaltsverzeichnis

Nervenheilkunde 2010; 29(04): 1-2
DOI: 10.1055/s-0038-1628757

Pharmakotherapie

Schattauer GmbH

Literatur

S. Arnold

,

G. Kluger

Abstract

Volltext

Referenzen

Literatur
1 Schuele SU, Lueders HO. Intractable epilepsy: management and therapeutic alternatives. Lancet Neurol 2008; 07: 514-24.
2 Ben-Menachem E. et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007; 48: 1308-17.
3 Ben-Menachem E. Lacosamide: an investigational drug for adjunctive treatment of partial-onset seizures. Drugs of Today 2008; 44: 35-40.
4 Beyreuther BK. et al. Lacosamide: a review of preclinical properties. CNS Drug Reviews 2007; 13: 21-42.
5 Doty P. et al. Lacosamide. Neurotherapeutics 2007; 04: 145-48.
6 Stöhr T, Wasterlain C. Lacosamide in in vitro and in vivo animal models for neuroprotection. PosterPräsentation bei der 60. Jahrestagung der American Epilepsy Society, San Diego, Dezember. 2006
7 Vimpat® Fachinformation; Stand. August 2008
8 Horstmann R. et al. SPM does not interact with valproic acid and carbamazepine. Poster-Präsentation bei der 57. Jahrestagung der American Epilepsy Society, Boston. Dezember 2003
9 Nickel B. et al. Population pharmacocinetics of lacosamide in subjects with partial-onset seizures: Results from two phase III trials. Poster-Präsentation bei der 62. Jahrestagung der American Epilepsy Society, Seattle. Dezember 2008
10 Halasz P. et al. Adjunctive lacosamide for partialonset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia 2009; 50: 443-53.
11 Chung S. et al. Lacosamide as adjunctive therapy for partial-onset seizures: A randomized controlled trial. Epilepsia Jan. 2010 Epub ahead of print.
12 Rosenfeld W. et al. Lacosamide: An interim Evaluation of long-term safety and efficacy as oral adjunctive therapy in subjects with partial-onset seizures. Poster-Präsentation der 61. Jahrestagung der American Epilepsy Society, Philadelphia. Dezember 2007
13 Rosenfeld W. et al. Long-term safety and tolerability of lacosamide for partial-onset seizures: an interim evaluation of patients exposed to lacosamide in double-blind and open-label trials. Poster-Präsentation der 63. Jahrestagung der American Epilepsy Society, Boston. Dezember 2009
14 Ben-Menachem E. et al. Long-term efficacy of lacosamide for partial-onset seizures: An interim evaluation of completer cohorts exposed to lacosamide for up to 36 months. Poster-Präsentation der 63. Jahrestagung der American Epilepsy Society, Boston. Dezember 2009
15 Gil-Nagel A. et al. The safety and tolerability of lacosamide in randomized, double-blind, placebo-controlled phase II/III clinical trials. Poster-Präsentation beim 28. Internationalen Epilepsiekongress, Budapest. Juli 2009
16 Biton V. et al. Intravenous lacosamide as replacement for oral lacosamide in patients with partialonset seizures. Epilepsia 2008; 49: 418-24.
17 Krauss G. et al. Intravenous lacosamide as shortterm replacement for oral lacosamide in partialonset seizures. Epilepsia. 2010 im Druck.
18 Wehner T. et al. Six months of postmarketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy center in Germany. Epilepsy Behav 2009; 16: 423-25.
19 Arnold S, Beige A. Lacosamide for the treatment of focal epilepsies: post-marketing experience in 40 patients. Poster-Präsentation der 63. Jahrestagung der American Epilepsy Society, Boston. Dezember 2009
20 Meencke H-J, Dehnicke C, Bartels S. Clinical experience with lacosamide in difficult to treat, drug resistant patients. Poster-Präsentation der 63. Jahrestagung der American Epilepsy Society, Boston. Dezember 2009
21 Schneider F. et al. Effectiveness and tolerability of lacosamide in adult patients with refractory partial epilepsy. Poster-Präsentation der 63. Jahrestagung der American Epilepsy Society, Boston. Dezember 2009
22 Mayer T, Lutz M. An open-label trial of lacosamide as add-on therapy for refractory partial-onset seizures. Poster-Präsentation der 63. Jahrestagung der American Epilepsy Society, Boston. Dezember 2009
23 Kellinghaus C. et al. Intravenous lacosamide for treatment of status epilepticus. Poster-Präsentation der 63. Jahrestagung der American Epilepsy Society, Boston. Dezember 2009
24 Almeida L, Soares-da-Silva P. Eslicarbazepine Acetate (BIA 2-093). Neurotherapeutics 2007; 04: 88-96.
25 Volosov A. et al. Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. Clin Pharmacol Ther 1999; 66: 547-53.
26 Bonifácio MJ. et al. Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: comparison with carbamazepine. Epilepsia 2001; 42: 600-8.
27 Benes J. et al. Anticonvulsant and sodium channelblocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives. J Med Chem 1999; 42: 2582-7.
28 Learmonth DA. et al. Synthesis, anticonvulsant properties and pharmacokinetic profile of novel 10,11-dihydro-10-oxo-5H-dibenz/b,f/azepine- 5-carboxamide derivatives. Eur J Med Chem 2001; 36: 227-36.
29 Bialer M. et al. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res 2004; 61: 1-48.
30 Almeida L. et al. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur J Clin Pharmacol 2008; 64: 267-73.
31 European Medicines Agency. CHMP assessment report for Zebinix. 2009 http://www.emea.europa.eu/humandocs/PDFs/EPAR/zebinix/H-988-en6 pdf; Stand 23.11.2009.
32 Almeida L, Soares-da-Silva P. Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. J Clin Pharmacol 2004; 44: 906-18.
33 Maia J. et al. Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093). Drugs R D 2005; 06: 201-6.
34 Almeida L. et al. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2—093) in healthy elderly and young subjects. J Clin Pharmacol 2005; 45: 1062-6.
35 Falcão A. et al. Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker. Biopharm Drug Dispos 2007; 28: 249-56.
36 Bialer M. et al. Investigation of the influence of eslicarbazepine acetate on the plasma concentrations of concomitant antiepileptic drugs in partial epilepsy. Epilepsia. 2009 50. (suppl.4): 156.
37 Fachinformation Zebinix, Stand. April 2009
38 Fuseau E. et al. Population pharmacokinetics of eslicarbazepine acetate in adult patients with refractory partial seizures. Epilepsia 2008; 49 (Suppl. 07) 432.
39 Elger C. et al. BIA-2093-301 Investigators Study Group. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: A randomized, doubleblind, placebo-controlled, parallel-group phase III study. Epilepsia 2009; 50: 454-63.
40 Gil-Nagel A. et al. BIA-2093-303 Investigators Study Group. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand 2009; 120: 281-7.
41 Halasz P. et al. Long-term treatment of partial epilepsy with eslicarbazepine acetate (ESL): Results of a one-year open-label extension to study BIA-2093-301. Epilepsia 2008; 49 (Suppl. 07) 435-6.
42 Gabbai AA. et al. Long-term treatment of partial epilepsy with eslicarbazepine acetate (ESL): Results of a one-year open-label extension to study BIA-2093-302. Epilepsia 2008; 49 (Suppl. 07) 432-3.
43 Lopes-Lima J. et al. Long-term treatment of partial epilepsy with eslicarbazepine acetate (ESL): Results of a one-year open-label extension to study BIA-2093-303. Epilepsia 2008; 49 (Suppl. 07) 441-2.
44 Levy RH. et al. (eds). Drugs in development – Rufinamide. In Antiepileptic drugs. 5th ed. Philadelphia: Lippincott Williams and Wilkins; 2002: 906-912.
45 McLean MJ. et al. The influence of rufinamide on sodium currents and action potential firing in rodent neurons (abstract). Epilepsia 2005; 46 (Suppl. 08) 269.
46 White HS. et al. The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure models. Epilepsia 2008; 49: 1213-20.
47 Bialer M. et al. Progress report on new antiepileptic drugs: A summary of the third Eilat conference. Epilepsy Res 1996; 25: 299-319.
48 Cheung WK. et al. Intraand intersubject variabilities of CGP 33101 after replicate single oral doses of two 200-mg tablets and 400-mg suspension. Pharm Res 1995; 12: 1878-82.
49 16 Eisai Ltd, Fachinformation Inovelon®, Stand. April 2008
50 Bialer M. et al. Progress report on new antiepileptic drugs: A summary of the fourth Eilat conference. Epilepsy Res 1999; 34: 1-41.
51 Svendsen KD. et al. Single center, open-label, multiple-dose pharmacokinetic trial investigating the effect of rufinamide administration on OrthoNovum 1/35 in healthy women [abstract]. Epilepsia 1998; 39 (Suppl. 06) 59.
52 Perucca E. et al. Rufinamide: Clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia 2008; 49: 1123-41.
53 Bialer M. et al. Progress report on new antiepileptic drugs: A summary of the fifth Eilat conference. Epilepsy Res 2001; 43: 11-58.
54 Arroyo S. Rufinamide. Neurother 2007; 04: 155-162.
55 Glauser T. et al. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008; 49: 1950-8.
56 Glauser T. et al. Open-label extension study of the efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome [abstract]. Epilepsia 2005; 46 (Suppl. 06) 408.
57 Kluger G. et al. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: First European experience. Epilepsy Behav 2009; 14: 491-5.
58 Krauss G, Perdomo C, Arroyo S. Short-term and long-term safety of rufinamide in patients with epilepsy [abstract]. Epilepsia 2005; 46 (Suppl. 08) 213.
59 Hancock E, Cross H. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev 2003; 03: CD003277.
60 Korff C. et al. Dravet syndrom (Severe Myoklonic Epilepsy in Infancy): A retrospective study of 16 Patients. Journal of Child Neurology 2007; 22: 185-194.
61 Desitin Arzneimittel GmbH, Hamburg. Diacomit® (Stiripentol). Produkt-Monographie. 2007
62 Trojnar MK. et al. Stiripentol. A novel antiepileptic drug. Pharmacological Reports 2005; 57: 154-160.
63 Quilichini P. et al. Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABAA-receptor channels. Epilepsia 2006; 47: 704-16.
64 Chiron C. et al. Stiripentol in severe myoclonic epilepsy in infancy: A randomized placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000; 356: 1638-1642.
65 Chiron C. Stiripentol. Expert Opin Investig Drugs 2005; 14: 905-911.
66 Chiron C. Stiripentol. Neurotherapeutics 2007; 04: 123-125.
67 Rascol O. et al. A pilot study of stiripentol, a new anticonvulsant drug, in complex partial seizures uncontrolled by carbamazepine. Clinical Neuropharmacology 1989; 12: 119-123.
68 Desitin Arzneimittel GmbH, Hamburg, Fachinformation Diacomit®; Stand Dezember. 2007
69 Perez J. et al. Stiripentol: Efficacy and tolerability in children with Epilepsy. Epilepsia 1999; 40: 1618-1626.
70 Chiron C. et al. Stiripentol in childhood partial epilepsy: randomizid placebo-controlled trial with enrichment and withdrawal design. Journal of Child Neurology 2006; 21: 496-502.
71 EPAR. European Public assessment Report. EMEA. 2007